(Q38235602)

31 August 2017

title

Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction (English)

1 reference

31 August 2017

main subject

ventricular dysfunction

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Jose Gomez-Arroyo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Marc A Simon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Erick Dominguez-Cano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Norbert F Voelkel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Harm J Bogaard

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

1 September 2014

1 reference

Proceedings of the American Thoracic Society

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1101-1115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079379%20AND%20SRC:MED&resulttype=core&format=json

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Pathobiology of pulmonary arterial hypertension and right ventricular failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Guidelines for the diagnosis and treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Updated treatment algorithm of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Current treatment strategies for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Aldosterone receptor antagonists in the medical management of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Prostacyclin and its analogues in the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Modern age pathology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Prostacyclin protects against elevated blood pressure and cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The role of endothelins and their receptors in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

An overview of endothelin signaling in the cardiac myocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Endothelin-1-dependent nuclear factor of activated T lymphocyte signaling associates with transcriptional coactivator p300 in the activation of the B cell leukemia-2 promoter in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Endothelin axis is upregulated in human and rat right ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Role of the natriuretic peptide system in cardiorenal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Riociguat for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Type 5 phosphodiesterase inhibition: the focus shifts to the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Experimental models of right heart failure: a window for translational research in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Possible role of imatinib in clinical pulmonary veno-occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Long term imatinib treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Adult cardiac stem cells are multipotent and support myocardial regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Drug-induced pulmonary arterial hypertension: a recent outbreak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Histone and chromatin cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Molecular signature of a right heart failure program in chronic severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Captopril in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The failing heart--an engine out of fuel

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Metabolic mechanisms in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Mechanism of the membrane depolarization induced by oxidative stress in guinea-pig ventricular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Stress-response hormesis and aging: "that which does not kill us makes us stronger".

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Cardiac-resynchronization therapy for mild-to-moderate heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Survival with cardiac-resynchronization therapy in mild heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO?

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Right ventricular failure after left ventricular assist device implantation: the need for an implantable right ventricular assist device

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Severe right heart failure after heart transplantation. A single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Mechanical support for isolated right ventricular failure in patients after cardiotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Successful conversion of TandemHeart left ventricular assist device to right ventricular assist device after implantation of a HeartMate XVE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Percutaneous mechanical support for the failing right heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension – A Multi-Center Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR

Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201312-425FR